Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GP0H
|
|||
| Former ID |
DNCL002084
|
|||
| Drug Name |
VGX-100
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Circadian Technologies
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor C (VEGFC) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| TNF signaling pathway | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Pathway Interaction Database | Alpha9 beta1 integrin signaling events | |||
| VEGF and VEGFR signaling network | ||||
| VEGFR3 signaling in lymphatic endothelium | ||||
| Reactome | Platelet degranulation | |||
| VEGF ligand-receptor interactions | ||||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01514123) Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 724066). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.